Sugen's Modest Financing Victory
Executive SummarySugen's strategy of a private placement of senior convertible debt solves a dilemma for biotechs that once had hot technologies but now find themselves lost with products in the early stages of clinical trials--how to raise money without diluting an already depressed stock price.
You may also be interested in...
December's ANDA rush has provided the largest monthly haul in two years. However, the month may be losing its influence over the US FDA's annual submission total.
Among the Korean firms presenting at J.P. Morgan, Hanmi laid out its strategy for obesity and other core pipeline assets, Celltrion focused on its expanding biosimilar pipeline and China plans and LG Chem unveiled new R&D progress.